Federal Register / Vol. 69, No. 212 / Wednesday, November 3, 2004 / Notices 64081

Contact Person: Chhanda L. Ganguly, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4120, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1739, gangulyc@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Neurobiology of HPA Axis Hormones and 

Transmitters ZRG1 IFCN D (02). 

Date: November 16, 2004. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Gamil C Debbas, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5170, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1018, debbasg@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Platelet 

Microparticles in Hemostasis. 

Date: November 16, 2004. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Delia Tang, MD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 4126, MSC 7802, 

Bethesda, MD 20892, (301) 435–2506, 

tangd@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ZRG1 

MOSS–G 01S: Musculoskeletal Tissue 

Engineering. 

Date: November 16–17, 2004. 

Time: 4 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Jurys Doyle Hotel, 1500 New 

Hampshire Avenue, NW., Washington, DC 

20036. 

Contact Person: Jean D. Sipe, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4106, 

MSC 7814, Bethesda, MD 20892, (301) 435–

1743, sipej@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Microbial 

Vaccine Development. 

Date: November 16, 2004. 

Time: 12 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037. 

Contact Person: Stephen M. Nigida, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4212, 

MSC 7812, Bethesda, MD 20892, (301) 435–

1222, nigidas@csr.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS)

Dated: October 27, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–24484 Filed 11–2–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Statement of Organization, Functions, 

and Delegations of Authority 

Part N, National Institutes of Health, 

of the Statement of Organization, 

Functions, and Delegations of Authority 

for the Department of Health and 

Human Services (40 FR 22859, May 27, 

1975, as amended most recently at 68 

FR 10743, March 6, 2003, and 

redesignated from Part HN as Part N at 

60 FR 56605, November 9, 1995), is 

amended as set forth below to reflect the 

elevation of the NIH Ethics Office from 

the Office of Management, Office of the 

Director, NIH, to the Office of the 

Director, NIH. 

Section N–B, Organization and 

Functions, under the heading Office of 

the Director (NA, formerly HNA) is 

amended as follows: 

Under the heading Office of the 

Director (NA, formerly HNA), insert the 

following: 

NIH Ethics Office (NAT, formerly 

HNAT). (1) Develops and administers 

the NIH policies for implementing the 

government-wide conflict of interest 

statutes and regulations, the HHS 

supplemental conflict of interest 

regulations, and HHS and NIH policies; 

(2) provides ethics policy guidance, 

training, and advice to: (a) The ICs’

ethics staffs, (b) Office of the Director, 

NIH, staff, and (c) employees whose 

Deputy Ethics Counselor (DEC) is the 

NIH DEC; and (3) coordinates the NIH 

response to requests from Congress, the 

Inspector General, DHHS and/or the 

Office of Government Ethics. 

Delegations of Authority Statement 

All delegations and redelegations of 

authority to officers and employees of 

NIH that were in effect immediately 

prior to the effective date of this 

establishment and are consistent with 

this amendment shall continue in effect, 

pending further redelegation.

Dated: September 14, 2004. 

Elias A. Zerhouni, 

Director, National Institutes of Health.

[FR Doc. 04–24480 Filed 11–2–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Public Health Service 

National Toxicology Program; National 

Institute of Environmental Health 

Sciences (NIEHS); National Institutes 

of Health (NIH) Notice of an Expert 

Panel Meeting To Assess the Current 

Validation Status of In Vitro Testing 

Methods for Identifying Potential 

Ocular Irritants; Request for 

Comments 

Summary 

Notice is hereby given of a meeting 

sponsored by the NIEHS and the 

National Toxicology Program (NTP), 

and organized by the NTP Interagency 

Center for the Evaluation of Alternative 

Toxicological Methods (NICEATM) in 

collaboration with the Interagency 

Coordinating Committee on the 

Validation of Alternative Methods 

(ICCVAM). At this meeting, an expert 

panel (‘‘Panel’’) will assess the current 

validation status and develop 

recommendations for further validation 

of in vitro test methods proposed for 

identifying substances that may cause 

serious eye damage. The meeting will 

take place on January 11–12, 2005, from 

8:30 a.m. to 5 p.m., at the National 

Institutes of Health (NIH), Natcher 

Center, Bethesda, MD. The meeting is 

open to the public with attendance 

limited only by the space available. 

Evaluation of In Vitro Ocular Test 

Methods Background 

In August 2003, the Scientific 

Advisory Committee on Alternative 

Toxicological Methods (SACATM) 

recommended that ICCVAM review the 

validation status of screening test 

methods that could be used to identify 

severe and irreversible ocular effects 

and carry out appropriate reviews of 

these test methods. In October 2003, the 

U.S. Environmental Protection Agency 

nominated several ocular-related 

activities to ICCVAM including 

evaluation of the validation status of 

four in vitro ocular toxicity test methods 

for screening for severe/irreversible 

ocular effects: (1) The Bovine Corneal 

Opacity and Permeability (BCOP) test; 

(2) the Hen’s Egg Test—Chorion 

Allantoic Membrane (HET–CAM); (3) 

the Isolated Rabbit Eye (IRE) test; and 

(4) the Isolated Chicken Eye (ICE) test. 

ICCVAM endorsed the review of the 

methods as a high priority and 

recommended that Background Review 

Documents be developed for each 

method by NICEATM in collaboration 

with the ICCVAM Ocular Toxicity 

Working Group. ICCVAM also